青光眼治疗的新策略。
Novel Therapeutics in Glaucoma Management.
机构信息
Section of Pharmacology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, Italy.
Center for Research in Ocular Pharmacology, CERFO, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, Catania, Italy.
出版信息
Curr Neuropharmacol. 2018;16(7):978-992. doi: 10.2174/1570159X15666170915142727.
BACKGROUND
Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and alterations of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms.
OBJECTIVE
An overview of the ultimate promising experimental drugs to manage glaucoma has been provided.
RESULTS
In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase inhibitors.
CONCLUSIONS
The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.
背景
青光眼是一种进行性视神经病变，其特征是视网膜神经节细胞死亡和视野改变。眼压升高（IOP）被认为是青光眼的主要危险因素，但其他因素如表观遗传机制也不能排除。
目的
本文综述了治疗青光眼的最终有前途的实验药物。
结果
特别是，我们集中讨论了嘌呤能配体、KATP 通道激活剂、气体（一氧化氮、一氧化碳和硫化氢）、非糖皮质激素甾体化合物、神经营养因子、PI3K/Akt 激活剂、胞磷胆碱、组蛋白去乙酰化酶抑制剂、大麻素、多巴胺和 5-羟色胺受体配体、小干扰 RNA 和 Rho 激酶抑制剂。
结论
本文还简要介绍了关于已在市场上存在的抗青光眼药物的潜在神经保护作用的最新报告。
Zotero 插件